PIK3CA and breast cancer: Given that PI3K pathway mutant breast cancers regress upon inhibition of GSH synthesis and cisplatin treatment in vivo, a similar metabolic vulnerability can be reasonably expected in SCC cancers and is seen in ESCCs [86,158].